Project Grant R61HL172269
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $793,184 to Northwestern University to conduct a 2x2 factorial randomized controlled trial. The study will evaluate the effects of two interventions to improve hypertension care: 1) automated transmission of remotely-obtained blood pressure values versus manual transmission, and 2) automatically-generated medical advice to patients via patient portal...
- This $1,410,766 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to analyze the effectiveness of ongoing natural experiments in telehealth for managing uncontrolled blood pressure (BP) during the COVID-19 pandemic. The project will leverage the PCORnet Blood Pressure Control Laboratory to track the implementation of new BP-related technologies and strategies across healthcare systems. Through descriptive and causal inference...
- This $570,390 Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837: Cardiovascular Diseases Research) supports research to evaluate and adapt an intervention for patients with uncontrolled hypertension to self-manage their blood pressure at home. The project aims to refine the process for identifying suitable patients, assess patient/provider perspectives, and optimize the intervention to the U.S. primary care context prior to a large-scale clinical trial....
- The University of Pennsylvania received a $692,846 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct the "Better Heart Study" on utilizing behavioral science strategies to increase hypertension diagnosis and treatment in India. The project aims to address barriers to clinic-based confirmatory blood pressure measurement and linkage to hypertension care through a randomized controlled trial testing two scalable...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) provides $942,143 to the Regents of the University of Michigan to evaluate the implementation of the WHO's HEARTS hypertension and diabetes primary care model in the Ministry of Health primary care system in Guatemala. The study aims to conduct a mixed-methods evaluation over a 30-month implementation period followed by a 30-month maintenance period to assess...
- This federal Project Grant award of $708,678, provided by the National Heart, Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to conduct a Sequential Multiple Assignment Randomized Trial (SMART) to reduce food insecurity and improve adherence in patients with hypertension. The key products and services to be delivered under this grant include: Determining the most effective initial food insecurity intervention (resource information or community health worker...
- The University of California, San Francisco (UCSF) was awarded a $1,795,978 Project Grant from the National Institute on Minority Health and Health Disparities (CFDA 93.307) on September 13, 2025. The goal of this 5-year study is to understand the hypertension (HTN) care cascade and cardiovascular disease risk among people with HIV who receive care at a safety net clinic, with a focus on the unique HTN care needs of those with severe financial challenges. The project will use quantitative...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,469,444.00 to the University of Alabama at Birmingham (UAB) to conduct a randomized clinical trial evaluating the impact of disseminating systolic blood pressure polygenic risk scores on blood pressure control, adherence to a healthy lifestyle, and cardiometabolic profile among 300 hypertensive adults aged 18-55 in the U.S. The trial aims to assess whether...
- The National Heart, Lung, and Blood Institute awarded a $623,433 Project Grant titled "Community Vital Signs (CVS): An Integrated Community-Based Approach to Identify Undiagnosed Hypertension in Nigeria" under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports a 5-year project to implement and assess community-based strategies to increase blood pressure screening rates and connections to care for hypertension management in Nigeria, a country with a high...
- This $661,129 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund a 5-year study by Northwestern University to develop and test a technology-enabled strategy to optimize blood pressure among reproductive-aged women with hypertension receiving care at Federally Qualified Health Centers. The project, titled "An Electronic Health Record-Based Strategy to Optimize Blood Pressure Among Pregnancy-Capable Adults in Primary Care:...
CONQUERING HYPERTENSION IN URBAN VIETNAM - PROJECT SUMMARY NATIONAL DATA FROM SEVERAL NON-COMMUNICABLE DISEASES (NCD) RISK FACTORS SURVEILLANCE SURVEYS IN VIETNAM HAVE SHOWN DISTURBING INCREASES IN THE PREVALENCE OF HTN BETWEEN 2010 AND 2020 (16% VS. 28%) IN PERSONS AGED 25-64 YEARS OLD. BOTH URBAN AND RURAL POPULATIONS SHOWED SIGNIFICANT INCREASES IN THE PREVALENCE OF HTN OVER TIME IN THESE SURVEYS, THOUGH URBAN (15% TO 31%) POPULATIONS DEMONSTRATED GREATER NEGATIVE TRENDS COMPARED TO RURAL (16% TO 27%) COMMUNITIES. THIS CAN BE ATTRIBUTED TO INCREASING ADVERSE LIFESTYLE PRACTICES, INCLUDING UNHEALTHY DIETS, PHYSICAL INACTIVITY, EXCESSIVE ALCOHOL CONSUMPTION, AND HIGH LEVELS OF STRESS. URBAN RESIDENTS WERE MORE LIKELY TO HAVE IMPORTANT NCD COMORBIDITIES AND REPORTED HAVING LESS TIME TO MANAGE THEIR HTN. THE NEED FOR A LARGE-SCALE AND SUSTAINABLE INTERVENTION APPROACH FOR HTN CONTROL IS EMPHASIZED IN THE 2022-2025 NATIONAL STRATEGIC PLAN OF VIETNAM. IN OUR RECENTLY COMPLETED NIH-FUNDED STUDY, WE DEVELOPED A MULTI-LEVEL, INTEGRATED APPROACH FOR CONTROLLING HTN AND SUCCESSFULLY DEPLOYED IT IN RURAL NORTHERN VIETNAM. PRELIMINARY RESULTS SHOWED THAT OUR INTERVENTION IS WELL-ACCEPTED AND EFFECTIVE. WE NOW PROPOSE TO ADAPT THIS WORK TAILORED TO AN URBAN VIETNAMESE SETTING USING INNOVATIVE IMPLEMENTATION STRATEGIES TO ENHANCE INTERVENTION DELIVERY (MHEALTH PLATFORM AND INTEGRATED HEALTH CARE DELIVERY SYSTEM). OUR INTERVENTION ADAPTATION PROCESS WILL BE GUIDED BY ADAPT-ITT MODEL. IMPLEMENTATION AND EVALUATION OF THE STUDY WILL BE GUIDED BY THE EPIS (EXPLORATION, PREPARATION, IMPLEMENTATION, AND SUSTAINMENT) FRAMEWORK. THE HTN-URBAN INTERVENTION INCLUDES THREE INTEGRATED COMPONENTS: (1) A STORYTELLING INTERVENTION; (2) HOME BP SELF-MONITORING; AND (3) EXPANDED COMMUNITY HEALTH WORKER SERVICES. OUR SPECIFIC AIMS FOR THE R61 PHASE ARE TO: 1) CONDUCT AN HTN NEEDS ASSESSMENT (30 SEMI-STRUCTURED INTERVIEWS) IN HAI PHONG CITY; 2) DEVELOP AND REFINE HTN-URBAN BASED ON THE RESULTS OF OUR HTN NEEDS ASSESSMENT AND THE ADAPT-ITT MODEL FOR ADAPTING A PROVEN INTERVENTION TO A NEW SETTING AND CONDITION. OUR SPECIFIC AIMS FOR THE R33 PHASE ARE TO 3) IMPLEMENT A CLUSTER RANDOMIZED TYPE II HYBRID EFFECTIVENESS AND IMPLEMENTATION TRIAL IN 14 COMMUNITIES IN HAI PHONG, INCLUDING 700 PATIENTS WITH UNCONTROLLED HTN, RANDOMIZED TO AN INTERVENTION (HTN-URBAN OF THREE INTEGRATED COMPONENTS) OR COMPARISON GROUP ("LEARN MORE" MODULE - DIDACTIC MATERIAL ONLY WITHOUT STORIES) TO ASSESS THE PRIMARY CLINICAL EFFECTIVENESS OUTCOME (CHANGES IN BP) AND IMPLEMENTATION OUTCOMES INCLUDING INTERVENTION ACCEPTABILITY, APPROPRIATENESS, FEASIBILITY, ADOPTION, AND FIDELITY; 4) PREPARE FOR DISSEMINATION OF HTN-URBAN BY INTEGRATION WITH THE NATIONAL STRATEGY ON PREVENTION AND CONTROL FOR NON-COMMUNICABLE DISEASES AND BUILDING CAPACITY IN POLICY-RELEVANT IMPLEMENTATION SCIENCE. THIS PROJECT WILL ADDRESS GAPS IN HYPERTENSION (HTN) CONTROL FOR ADULTS LIVING IN URBAN SETTING IN VIETNAM BY TESTING A MULTI- LEVEL, EVIDENCE-BASED INTERVENTION WITH THE PROMISE OF NATIONWIDE SCALABILITY AND SUSTAINABILITY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/18/25 | ||
| Not listed | $724.1k | 3/11/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
SUB00000467S | Health Strategy And Policy Institute | Project Grant R61HL172269 | $205.4k | 7/3/24 |